These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. Lu PH; Negrin RS J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209 [TBL] [Abstract][Full Text] [Related]
3. Human cytotoxic effector cells: definition and analysis of activity. Ortaldo JR Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345 [TBL] [Abstract][Full Text] [Related]
4. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology. Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457 [TBL] [Abstract][Full Text] [Related]
5. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341 [TBL] [Abstract][Full Text] [Related]
6. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells. Arancia G; Malorni W; Donelli G Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107 [TBL] [Abstract][Full Text] [Related]
8. Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo. Wang J; He M; Shi W; Sha H; Feng J; Wang S; Wang Y Cancer Invest; 2009 Mar; 27(3):244-50. PubMed ID: 19194830 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690 [TBL] [Abstract][Full Text] [Related]
10. Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells. Zhu XL; Lin ZB Acta Pharmacol Sin; 2005 Sep; 26(9):1130-7. PubMed ID: 16115382 [TBL] [Abstract][Full Text] [Related]
11. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236 [TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of anti-CD3-induced activated killer cells. Yun YS; Hargrove ME; Ting CC Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087 [TBL] [Abstract][Full Text] [Related]
14. The CD56 adhesion molecule is the major determinant for detecting non-major histocompatibility complex-restricted cytotoxic mononuclear cells from the intestinal lamina propria. Van Tol EA; Verspaget HW; Peña AS; Kraemer CV; Lamers CB Eur J Immunol; 1992 Jan; 22(1):23-9. PubMed ID: 1370415 [TBL] [Abstract][Full Text] [Related]
15. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871 [TBL] [Abstract][Full Text] [Related]
16. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses. Zhu BQ; Ju SW; Shu YQ Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623 [TBL] [Abstract][Full Text] [Related]
17. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status. Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694 [TBL] [Abstract][Full Text] [Related]
18. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815 [TBL] [Abstract][Full Text] [Related]
19. Can the dual-functional capability of CIK cells be used to improve antitumor effects? Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of cytokine-induced killer cells against human lung cancer. Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]